Biocon and Carnegie receive FDA tentative approval for Rifaximin tablets
Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy
Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Investment to expand manufacturing and global medicine supply capacity
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Takeda will seek an external partner to leverage its cell therapy platform technologies
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
India currently hosts more than 10,075 biotech startups
Subscribe To Our Newsletter & Stay Updated